Zacks Research Has Positive Outlook of BIO FY2024 Earnings

Bio-Rad Laboratories, Inc. (NYSE:BIO) – Analysts at Zacks Research boosted their FY2024 earnings per share estimates for shares of Bio-Rad Laboratories in a research note issued on Wednesday, November 20th. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings of $10.18 per share for the year, up from their prior estimate of $9.46. The consensus estimate for Bio-Rad Laboratories’ current full-year earnings is $10.29 per share. Zacks Research also issued estimates for Bio-Rad Laboratories’ Q4 2025 earnings at $3.28 EPS, FY2025 earnings at $11.44 EPS, Q1 2026 earnings at $3.15 EPS and Q2 2026 earnings at $3.08 EPS.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings results on Wednesday, October 30th. The medical research company reported $2.01 EPS for the quarter, topping analysts’ consensus estimates of $1.16 by $0.85. Bio-Rad Laboratories had a positive return on equity of 3.74% and a negative net margin of 30.18%. The company had revenue of $649.70 million during the quarter, compared to analysts’ expectations of $628.18 million. During the same quarter in the previous year, the firm earned $2.33 EPS. Bio-Rad Laboratories’s revenue was up 2.8% on a year-over-year basis.

Other equities analysts have also recently issued research reports about the company. Citigroup boosted their price target on Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Wells Fargo & Company assumed coverage on Bio-Rad Laboratories in a research report on Tuesday, August 27th. They set an “equal weight” rating and a $340.00 price objective on the stock. Royal Bank of Canada boosted their price objective on Bio-Rad Laboratories from $446.00 to $469.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. Finally, StockNews.com upgraded Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Friday, November 1st. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, Bio-Rad Laboratories currently has a consensus rating of “Moderate Buy” and a consensus price target of $391.80.

Bio-Rad Laboratories Price Performance

Bio-Rad Laboratories stock opened at $338.24 on Monday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.52 and a current ratio of 6.14. Bio-Rad Laboratories has a 52 week low of $262.12 and a 52 week high of $387.99. The stock has a market capitalization of $9.47 billion, a P/E ratio of -12.36 and a beta of 0.93. The stock has a fifty day moving average of $340.63 and a 200-day moving average of $316.68.

Insider Buying and Selling at Bio-Rad Laboratories

In other Bio-Rad Laboratories news, EVP James Barry sold 623 shares of the company’s stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $330.49, for a total value of $205,895.27. Following the sale, the executive vice president now owns 147 shares in the company, valued at approximately $48,582.03. The trade was a 80.91 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Andrew J. Last sold 3,000 shares of the company’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $329.94, for a total value of $989,820.00. Following the completion of the sale, the chief operating officer now owns 7,559 shares in the company, valued at $2,494,016.46. This trade represents a 28.41 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 17.50% of the company’s stock.

Institutional Investors Weigh In On Bio-Rad Laboratories

A number of institutional investors have recently made changes to their positions in the stock. Van ECK Associates Corp acquired a new position in shares of Bio-Rad Laboratories in the 2nd quarter valued at about $180,040,000. First Eagle Investment Management LLC lifted its stake in shares of Bio-Rad Laboratories by 32,296.9% in the 2nd quarter. First Eagle Investment Management LLC now owns 636,275 shares of the medical research company’s stock valued at $173,773,000 after purchasing an additional 634,311 shares during the period. Point72 Asset Management L.P. acquired a new position in shares of Bio-Rad Laboratories in the 3rd quarter valued at about $83,681,000. Dimensional Fund Advisors LP lifted its stake in shares of Bio-Rad Laboratories by 64.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 494,604 shares of the medical research company’s stock valued at $135,081,000 after purchasing an additional 193,700 shares during the period. Finally, Select Equity Group L.P. lifted its stake in shares of Bio-Rad Laboratories by 26.2% in the 2nd quarter. Select Equity Group L.P. now owns 649,522 shares of the medical research company’s stock valued at $177,391,000 after purchasing an additional 134,856 shares during the period. Institutional investors own 65.24% of the company’s stock.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.